Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Inv ...

Exhibit 99.1 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024 Ged ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware 87-0455038 (State or other jurisdiction (IRS Employer ...

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinicalstage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review. "We are pleased to announce the plans for this novel, exp ...

ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review. The primary goal of the planned Phase 2 trial will be to establish efficacy of neoadjuvant Gedeptin therapy combined with an immune checkpoint inhibitor in first-recurrenc ...

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinicalstage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review. GeoVax and a specially convened clinical advisory committ ...

Core Insights - The article highlights the relevance of GeoVax's stock (GOVX) due to its advancements in developing a next-generation Covid-19 vaccine, GEO-CM04S1, which has received funding from the Biomedical Advanced Research and Development Authority (BARDA) [2][3][5] Company Developments - GeoVax has partnered with Allucent to conduct a Phase 2b clinical trial for its GEO-CM04S1 Covid vaccine, which has led to a significant increase in GOVX stock price, rising over 110% before some gains were pared back [5] - The Phase 2b trial will involve 10,000 participants and aims to evaluate the efficacy of GEO-CM04S1 against an already approved Covid vaccine, with the unique feature of delivering multiple antigens in a single dose [8] Industry Context - The ongoing concern regarding Covid-19, particularly among vulnerable populations with chronic diseases, underscores the need for more effective vaccines, thereby enhancing the relevance of GeoVax's developments in the biotech sector [3]

Exhibit 99.1 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad ef icacy of the vaccine candidate Significant milestone achieved towards implementation of a commercially validated manufacturing system Progress across pipeline with planned data readouts for GEO-CM04S1 in multiple trials and Gedeptin® in healthy patient boost trial on track f ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations, Stern IR David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Robert LeBoyer - Noble Capital Markets Operator Good afternoon, and welcome everyone to the GeoVax First Quarter 2024 Corporate Update Call. My name is Ma ...

For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) 1900 Lake Park Drive, Suite 38 ...